Inclusion Criteria:

          1. Patients must have histologically confirmed, unresectable stage IIIc or stage IV
             metastatic melanoma, as defined by the American Joint Committee on Cancer 7th edition.
             Unresectability of stage IIIc disease must have confirmation from a surgical
             oncologist;

          2. Patients with advanced melanoma who have received one prior immunotherapy systemic
             regimen for advanced disease, for whom vemurafenib/cobimetinib treatment has been
             scheduled by the treating physician.

          3. Adjuvant treatment is allowed, except for anti-PD-1, anti-PD-L1, anti-PD-L2,
             anti-CD137, or anti-CTLA-4 agents;

          4. Patients must be naïve to treatment for locally advanced unresectable or metastatic
             with BRAF/MEK inhibitors;

          5. Documentation of BRAFV600 mutation-positive status in melanoma tumor tissue BRAF V600
             mutation test;

          6. At least one measurable lesion according to disease per RECIST v1.1 criteria;

          7. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0- 2;

          8. Male or female patient aged ≥ 18 years;

          9. Able to participate and willing to give written informed consent prior to performance
             of any study-related procedures and to comply with the study protocol;

         10. Life expectancy ≥ 12 weeks.

        Exclusion Criteria:

          1. History of any prior systemic treatment for unresectable stage IIIc or stage IV
             melanoma (prior anti RAF or MEK agents) other than one prior first-line immunotherapy;

          2. Palliative radiotherapy within 14 days prior to the first dose of study treatment;

          3. Major surgery or traumatic injury within 14 days prior to first dose of study
             treatment;

          4. Patients with active malignancy (other than BRAF- mutated melanoma) or a previous
             malignancy within the past 3 years are excluded; except for patients with resected
             melanoma, resected BCC,resected cutaneous SCC, resected melanoma in-situ, resected
             carcinoma in-situ of the cervix, and resected carcinoma in-situ of the breast;
             Exclusion Criteria Based on Organ Function.

             Ocular:

          5. History of, or evidence of retinal pathology on ophthalmologic examination that is
             considered a risk factor for neurosensory retinal detachment/central
             serouschorioretinopathy (CSCR), retinal vein occlusion (RVO) or neovascularmacular
             degeneration;

          6. The risk factors for RVO are listed below. Patients will be excluded if they currently
             have the following conditions:

               1. Uncontrolled glaucoma with intra-ocular pressures ≥21 mmHg;

               2. Serum cholesterol ≥Grade 2;

               3. Hypertriglyceridemia ≥ Grade 2;

               4. Hyperglycemia (fasting) ≥Grade 2;

             Cardiac:

          7. History of clinically significant cardiac dysfunction, including the following:

               1. Current unstable angina;

               2. Symptomatic congestive heart failure of New York Heart Association class 2 or
                  higher;

               3. History of congenital long QT syndrome or mean (average of triplicate
                  measurements) QTcF ≥ 450 msec at baseline or uncorrectable abnormalities inserum
                  electrolytes (sodium, potassium, calcium, magnesium, phosphorus);

               4. Uncontrolled hypertension≥ Grade 2 (patients with a history hypertension
                  controlled with anti-hypertensives to ≤ Grade 1 are eligible);

               5. Left ventricular ejection fraction (LVEF) below institutional lower limit of
                  normal (LLN) or below 50%, whichever is lower.

             Central Nervous System:

          8. Patients with active/symptomatic CNS lesions are excluded.